CureVac (NASDAQ:CVAC) | Finanzwire

Basculer en Français

10936	Companies
238805	Keywords
167666	Articles
128365	Press releases

Home
Companies
CureVac

PRESS RELEASE

published on 11/04/2024 at 13:03, 1 year 10 months ago

CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer
CureVac appoints Axel Sven Malkomes as CFO, bringing 30 years of industry experience. His role will drive strategic initiatives, financial foundation, and shareholder value

Biopharmaceutical Company CFO MRNA Technology CureVac Axel Sven Malkomes
PRESS RELEASE

published on 11/04/2024 at 13:00, 1 year 10 months ago

CureVac to Present at the 12th International mRNA Health Conference
CureVac to present new data at the 12th International mRNA Health Conference, showcasing developments in mRNA cancer vaccine and lipid nanoparticle delivery technology

Innovation Biopharmaceutical CureVac MRNA Platform MRNA Health Conference
BRIEF

published on 10/28/2024 at 13:05, 1 year 10 months ago

CureVac to Present New Findings at SITC Annual Meeting

Clinical Trials MRNA Technology Cancer Vaccine CureVac SITC Meeting
PRESS RELEASE

published on 10/28/2024 at 13:00, 1 year 10 months ago

CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
CureVac to present at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, sharing immunogenicity data on mRNA-based cancer vaccine CVGBM. Conference details and contact info provided

CureVac MRNA Poster Presentation Immunogenicity Society For Immunotherapy Of Cancer
BRIEF

published on 09/13/2024 at 14:02, 1 year 11 months ago

CureVac's CVGBM Cancer Vaccine Shows Promising Results in Phase 1 Glioblastoma Study

CureVac Glioblastoma CVGBM Phase 1 Study T-cell Responses
PRESS RELEASE

published on 09/13/2024 at 13:57, 1 year 11 months ago

CureVac’s CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress
CureVac's CVGBM Cancer Vaccine induces promising immune responses in Phase 1 Study in Glioblastoma presented at ESMO 2024 Congress. Results show de novo T-cell activity & acceptable safety profile up to 100 µg dose

Cancer Vaccine CureVac CVGBM Phase 1 Study Immune Responses
BRIEF

published on 09/12/2024 at 13:02, 1 year 11 months ago

CureVac and GSK Report Positive Phase 2 Data for Influenza mRNA Vaccine

MRNA Technology Influenza Vaccine Phase 2 Results GSK Partnership CureVac Milestone
PRESS RELEASE

published on 09/12/2024 at 12:57, 1 year 11 months ago

CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program
CureVac Partner GSK reports positive Phase 2 results for seasonal influenza mRNA vaccine program. Data show immune responses to A and B strains with acceptable safety profile

GSK CureVac Phase 2 MRNA Vaccine Seasonal Influenza
BRIEF

published on 09/09/2024 at 13:05, 1 year 11 months ago

CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress

Clinical Data CureVac MRNA Vaccine Glioblastoma ESMO Congress
PRESS RELEASE

published on 09/09/2024 at 13:00, 1 year 11 months ago

CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress
CureVac to present first CVGBM Glioblastoma cancer vaccine clinical data at ESMO 2024 Congress. First-in-human study results to be shared, highlighting mRNA technology's potential for cancer vaccines

MRNA Technology CureVac Glioblastoma CVGBM ESMO 2024 Congress

Accesswire

Published on 09/04/2026 at 23:30, 4 hours 13 minutes ago

FutureGen Industries Announces Shares for Debt Settlement
Published on 09/04/2026 at 23:00, 4 hours 43 minutes ago

Golden Minerals Announces Management Change and Argentine Project Update
Published on 09/04/2026 at 22:30, 5 hours 13 minutes ago

Panther Minerals Closes Brokered Private Placement of $3,000,000
Published on 09/04/2026 at 14:30, 13 hours 13 minutes ago

Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF)
Published on 09/04/2026 at 14:00, 13 hours 43 minutes ago

Horizon Aircraft Appoints Tom Hearne to Board of Directors and Names Him Audit Committee Chair

View all ACCESSWIRE

EQS Group

Published on 09/04/2026 at 22:10, 5 hours 33 minutes ago

Quantinuum to Participate in the Bernstein 23rd Annual Pan-European Strategic Decisions Conference
Published on 09/04/2026 at 19:20, 8 hours 23 minutes ago

Dahua Technology Showcases Integrated Smart Living and Innovations at IFA Berlin 2026
Published on 09/04/2026 at 18:55, 8 hours 48 minutes ago

Holding(s) in Company
Published on 09/04/2026 at 18:50, 8 hours 53 minutes ago

A&S Resources secures railway funding of USD$6 Billion to unlock $2.5 trillion iron ore asset
Published on 09/04/2026 at 18:05, 9 hours 38 minutes ago

Grundig Unveils New Product Lineup at IFA 2026, Marking a New Phase in Strategic Partnership

Les Echos

Published on 09/04/2026 at 18:57, 8 hours 46 minutes ago

Disclosure of transactions in own shares from September 1 to September 4, 2026
Published on 09/04/2026 at 17:45, 9 hours 58 minutes ago

Declaration of voting rights at the end of August 2026
Published on 09/04/2026 at 17:45, 9 hours 58 minutes ago

DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS
Published on 09/04/2026 at 16:00, 11 hours 43 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of July 31, 2026
Published on 09/04/2026 at 16:00, 11 hours 43 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of August 31, 2026

View all LES ECHOS COMFI WIRE